


Image  
1651-1652

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inside application : MICHAEL VALENTINE AGREZ, ET AL.  
Application No. : 10/019,816  
Filed : March 27, 2002  
Confirmation No. : 9944  
For : METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR  
ACTIVITY AND AGENTS USEFUL FOR SAME  
Examiner :  
Attorney's Docket : SW-046XX (now BLAKE-046XX)

TC Art Unit: 1651

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450 on Oct. 23, 2003.

By: Holliday C. Heine  
Holliday C. Heine  
Registration No. 34,346  
Attorney for Applicant(s)

\*\*\*\*\*

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the  
enclosed references listed on the attached copy of PTO Form #1449. The  
paragraph(s) marked below are applicable to this Information Disclosure  
Statement.

[ ] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached  
Information Disclosure Statement is being filed within three  
months of the filing date of the above identified national  
application or within three months of the date of entry of the  
national stage as set forth in 37 C.F.R. § 1.491 of the above  
identified application. Accordingly, applicant(s) believes that  
no fee or statement under 37 C.F.R. § 1.97(e) is required.

- ☒ (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- ☐ a statement under 37 CFR § 1.97(e); or
- ☐ the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- ☐ (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- ☐ (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- ☐ (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of

Application No.: 10/019,816  
Filed: March 27, 2002  
TC Art Unit: 1651  
Confirmation No.: 9944

information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

Five of the 15 cited references are enclosed herewith; the other ten references will be forwarded to the U.S. Patent Office as soon as they are received by the undersigned.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.


By: Holliday C. Heine  
Holliday C. Heine  
Registration No. 34,346  
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEBOVICI LLP  
Ten Post Office Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

CLG/mc/297453-1  
Enclosure

Date: October 23, 2003

Page 1 of 2

 <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				ATTY. DOCKET NO.		APPLICATION NO.	
				SW-046XX (now BLAKE-046XX)		10/019,816	
				APPLICANT: Michael Valentine Agrez, et al.			
				FILING DATE		TC ART UNIT	
				March 27, 2002		1651	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION/ ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE
		US					
		US					
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		** WO 01/00677	Publ 1/4/2001	PCT			
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)</b>							
		Boulton, T.G., et al., "Mitogen-activated protein kinase 1," (EC 2.7.1) (1991) (Swiss Prot Acc No. P27703) .					
		** Breuss, J.M., et al., "Restricted distribution of integrin $\beta 6$ mRNA in primate epithelial tissues," J Histochem Cytochem (1993), 41: 1521-1527.					
		Carloni, V., et al., "The integrin $\alpha 6 \beta 1$ , is necessary for the matrix-dependent activation of FAK and MAP Kinase and the migration of human hepatocarcinoma cells," Hepatology 2001, Jul; 34(1): 42-9. (PUBMED ABSTRACT)					
		** Eliceira, B.P., et al., "The role of $\alpha v$ integrins during angiogenesis: insights into potential mechanisms of action and clinical development," J Clin Invest (1999), 103(9): 1227-30.					
		** Eliceira, B.P., et al., "Integrin $\alpha v \beta 3$ requirement for sustained mitogen activated protein kinase activity during angiogenesis," J Cell Biol (1998), 140(5): 1255-63.					
		** Friedlander, M., et al., "Definition of two angiogenic pathways by distinct $\alpha v$ integrins," Science (1995), 270(5241): 1500-2.					
		Gonzales, F.A., " <i>H Sapiens</i> 40kDa protein kinase related to rat ERK2," (1992) (GenPept Acc No. CAA77753).					
		** Gupta, K., et al., "VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signalling," Exp Cell Res (1999), 247(2): 495-504.					
		Ishii, T., et al., "Integrin-linked Kinase Controls Neurite Outgrowth in N1E-115 Neuroblastoma Cells," J. Biol. Chem. (2001), 276(46): 42994-43003.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**\*\* REFERENCES WILL BE FURNISHED TO U.S. PTO AS SOON AS AVAILABLE**



Date: October 23, 2003

Page 2 of 2

<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b>  SW-046XX (now BLAKE-046XX)	<b>APPLICATION NO.</b>  10/019,816
	<b>APPLICANT:</b> Michael Valentine Agrez, et al.	
	<b>FILING DATE</b> March 27, 2002	<b>TC ART UNIT</b> 1651

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION/ ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE
	US					
	US					

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS** (including Author, Title, Date, Pertinent Pages, etc.)

	** Pages, G., et al., "Signaling angiogenesis via p42/p44 MAP kinase cascade," Ann NY Acad Sci (2000), 902: 187-200.
	** Redlitz, A., et al., "Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells." J Vasc Res (1999), 36(1): 28-34.
	Sugiura, N., et al., "Mus musculus DNA for ERK2," exon 7 (1997) (GenPept Acc No. BAA22620).
	** Tanaka, K., et al., "Roles of extracellular signal-regulated kinase 1 / 2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis," Jpn J Cancer Res (1999), 90(6): 647-54.
	** Yu, Y., et al., "MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor," J Cell Physiol (1999), 178(2): 235-46.

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

HCH/mc/297502-1

**\*\* REFERENCES WILL BE FURNISHED TO U.S. PTO AS SOON AS AVAILABLE**